Vaginal Yeast Infection

No. A vaginal yeast infection is caused by an overgrowth of Candida, a fungus that normally lives in the vagina, gut, and skin, not by a pathogen transmitted through sexual contact. You can develop a yeast infection without any sexual activity, and it is not classified as a sexually transmitted disease by the CDC. Sexual activity can occasionally disrupt vaginal flora and trigger an episode, and a partner can rarely be affected, but the underlying mechanism (endogenous microbiome imbalance) is fundamentally different from STI transmission. Treatment of sexual partners is not routinely recommended.

These three conditions all cause vaginal discomfort and discharge, but each has a distinctive clinical fingerprint. VVC: intense vulvar itch, thick white cottage-cheese discharge, no odor (or mild yeasty scent), normal vaginal pH ≤4.5. BV: mild itch or none, thin gray-white watery discharge, fishy odor (especially after sex or during menstruation), elevated pH >4.5: needs antibiotics, not antifungals. Trichomoniasis: frothy, yellow-green discharge, odor, elevated pH >4.5, often causes more pronounced burning and redness: also needs antibiotics (metronidazole or tinidazole), not antifungals. Because treatments don't overlap, getting the right diagnosis before treating is essential. A clinician can distinguish all three in a single visit with a pH test and wet-mount microscopy.

For an uncomplicated yeast infection with a classic pattern, OTC topical azoles (miconazole, clotrimazole, tioconazole) and prescription oral fluconazole 150 mg are equally effective, both achieve negative cultures in approximately 80–90% of treated uncomplicated cases. OTC topicals are available immediately without a prescription but must be applied correctly for 1–7 days depending on the product; they can degrade latex condoms and diaphragms. Oral fluconazole is a single-pill convenience option requiring a prescription in the U.S. (approximately $5–$15 generic) and is avoided in pregnancy. Prescription-only topicals (butoconazole, terconazole) and boric acid suppositories are reserved for cases that fail OTC treatment or involve non-albicans species confirmed by culture. Never switch between multiple OTC products hoping for a different result: if OTC treatment has failed, a culture and clinician evaluation are needed.

With appropriate treatment, symptoms typically begin improving within 24–48 hours and fully resolve within 3–7 days. Single-dose oral fluconazole may take up to 72 hours to produce noticeable relief because tissue levels must build before the drug reaches adequate antifungal concentrations at the vaginal mucosa. OTC topical creams or suppositories often provide faster local symptom relief (burning and itching may ease within hours of application) but must be used for the full prescribed duration, 1, 3, or 7 days depending on the product, even if symptoms improve early. If symptoms have not meaningfully improved after one week, or return within two weeks, see a clinician, either the diagnosis was wrong or the Candida species is azole-resistant.

Recurrent vulvovaginal candidiasis (RVVC, defined as 4 or more confirmed episodes per year) affects approximately 5–8% of women and usually signals an underlying factor sustaining the imbalance. Common drivers include: uncontrolled or undiagnosed blood sugar elevation (diabetes, prediabetes); immune suppression (HIV, chemotherapy, high-dose steroids); high-dose estrogen (hormonal contraceptives or hormone therapy); repeated antibiotic courses; and, critically, a non-albicans Candida species such as C. glabrata or C. tropicalis that is intrinsically resistant to fluconazole. A clinician should order a fungal culture with species ID and susceptibility testing, evaluate for underlying causes, and discuss a 6-month suppressive maintenance regimen to break the recurrence cycle.

Antibiotics eliminate not just the target pathogenic bacteria but also the protective Lactobacillus species that normally dominate the vaginal microbiome, keep pH acidic, and produce hydrogen peroxide and lactic acid that inhibit Candida overgrowth. When lactobacilli are depleted, Candida, a fungus completely unaffected by antibacterial drugs, rapidly expands to fill the ecological niche. Broad-spectrum antibiotics (amoxicillin-clavulanate, fluoroquinolones, clindamycin) carry the highest risk. Approximately 28–33% of women develop VVC during or immediately after antibiotic treatment. If you reliably develop a yeast infection after antibiotics, ask your clinician about a single prophylactic dose of fluconazole, this is a CDC-recognized strategy for reducing antibiotic-triggered VVC.

Yes: yeast infections are more common during pregnancy due to higher estrogen levels and increased vaginal glycogen, and treating them is safe and recommended. The only regimen approved for use during pregnancy is a 7-day course of topical vaginal antifungal: miconazole or clotrimazole, applied intravaginally each night for 7 days. Oral fluconazole is generally avoided during pregnancy: observational studies have raised concern about a possible association between repeated first-trimester fluconazole exposure and adverse fetal outcomes, including cardiac septal defects, though absolute risk estimates remain debated. Topical therapy is equally effective and eliminates this concern. Untreated VVC can transmit Candida to the newborn during delivery, causing oral thrush or diaper rash, so treatment before delivery is worthwhile.

Yes, though it is uncommon. A male partner can develop penile candidiasis (balanitis), symptoms include redness, itching, burning, and a rash or white patches on the glans penis, with an estimated risk of approximately 15% after unprotected sex with a partner who has an active vaginal yeast infection. Most cases in male partners resolve with 7 days of OTC topical antifungal cream (clotrimazole or miconazole) applied to the affected area. Men who are uncircumcised, have diabetes, or are immunocompromised are at meaningfully higher risk of symptomatic penile candidiasis. Routine treatment of male partners when only the female partner has symptoms is not recommended by CDC or ACOG guidelines.

It is generally advisable to abstain from sex until treatment is complete and symptoms have fully resolved. Intercourse during active VVC can worsen vulvar irritation and mechanical inflammation, and you can transmit Candida to a partner (though at relatively low rates). If you are using oil-based topical antifungal creams or vaginal suppositories, these degrade latex condoms and diaphragms, reducing their effectiveness as contraception and STI prevention. Oral fluconazole does not interfere with latex barriers. Resuming sex once you are symptom-free is safe.

Boric acid is a naturally occurring antifungal compound used as an intravaginal suppository (600 mg daily for 3 weeks / 21 days) for two specific situations: (1) confirmed non-albicans Candida infections (such as C. glabrata) that are resistant or poorly responsive to standard azoles, and (2) recurrent VVC that has not responded adequately to fluconazole maintenance. It is recommended in CDC STI Treatment Guidelines and ACOG guidance as an alternative for these resistant or recurrent cases, with studies showing remission rates of approximately 70–80% in fluconazole-resistant infections. Boric acid is NOT a first-line treatment for uncomplicated VVC, is NOT safe during pregnancy (embryotoxic, must be avoided), and is for intravaginal use only, boric acid is toxic if ingested. It requires clinician guidance, not OTC self-selection.

A clinician checks vaginal pH with a simple pH strip. VVC shows normal acidic pH (≤4.5), which immediately helps distinguish it from BV (typically pH >4.5) and trichomoniasis (typically pH >4.5). A KOH wet-mount follows: potassium hydroxide is added to a vaginal swab sample on a glass slide, dissolving epithelial cells and revealing Candida hyphae, pseudohyphae, or budding yeast under a microscope, results are immediate and available in the same office visit. For recurrent or treatment-resistant cases, a fungal culture (sent to the microbiology lab, results in 2–5 days) identifies the exact Candida species and allows antifungal susceptibility testing, critical because non-albicans species will not respond to fluconazole and require different targeted therapy.

Yes, and this is a genuinely important clinical concern. A yeast infection does not protect against or rule out a concurrent STI. Chlamydia and gonorrhea are frequently asymptomatic in the cervix while a vaginal yeast infection is producing prominent itching and discharge, meaning the STI is easily missed while the VVC gets treated. Trichomoniasis symptoms overlap closely with VVC. If you have any risk factors for an STI, a new partner, unprotected sex, or exposure to someone with a known STI, it is worthwhile testing for STIs at the same visit, even when VVC symptoms are prominent. A clinician can test for VVC, BV, trichomoniasis, chlamydia, and gonorrhea in a single visit.

Both can cause burning on urination, but the distinguishing features are different. A yeast infection causes burning primarily during or just after urination (external vulvar burning as urine contacts inflamed skin), accompanied by intense itching, vulvar redness, and thick white discharge. A UTI (urinary tract infection) causes burning primarily during urination that originates internally, frequent and urgent urination with small volumes, cloudy or blood-tinged urine, and often little to no vaginal discharge or itching. A UTI requires antibiotics (trimethoprim-sulfamethoxazole, nitrofurantoin), antifungals will not treat it. A urine dipstick or culture at any clinic distinguishes the two quickly. Some women experience both simultaneously, particularly after intercourse: in that case, both need treatment.